Subscribe to RSS

DOI: 10.1055/s-0045-1814419
Multiple Unusual Distant Metastasis in TENIS: Comparative Evaluation of [18F]FDG and [68Ga]-FAPI-04 PET-CT Uptake Patterns at Metastatic Sites
Authors
Abstract
A relatively uncommon occurrence of multiple unusual distant metastasis in a patient with thyroglobulin-elevated negative iodine scintigraphy (TENIS) (subcutis, skeletal muscle, kidney, and pericardium) is presented. A 65-year-old man with papillary thyroid carcinoma post two cycles of radioactive iodine therapy on subsequent follow-up showed elevated serum thyroglobulin (>300 ng/mL) and negative iodine scintigraphy (TENIS). [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) for disease restaging revealed extensive metastatic disease involving cervical and mediastinal nodes, bones, liver, subcutis, skeletal muscle, kidney, and pericardium. [68Ga]-fibroblast activation protein inhibitor (FAPI)-04 PET/CT was done to evaluate for fibroblast activation protein (FAP) expression, and the feasibility of targeted radionuclide therapy showed nil to very low FAP expression at the metastatic sites, except for the few cervical and mediastinal nodes, subcutaneous nodule in the left arm, and L3 vertebral lesion. In addition to illustrate the rare presentation in TENIS, this case demonstrates the superiority of [18F]-FDG PET/CT over FAPI PET/CT in this patient. However, FAPI-PET/CT may be used as a theranostic tool for assessing radionuclide therapy prospects in selected cases.
Keywords
thyroid cancer - TENIS - unusual distant metastasis - 18F-FDG PET/CT - [68Ga]-FAPI-04 PET/CTPublication History
Article published online:
23 December 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Basu S, Dandekar M, Joshi A, D'Cruz A. Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap. Eur J Nucl Med Mol Imaging 2015; 42 (08) 1167-1171
- 2 Vijayan R, Palaniswamy SS, Vadayath UM, Nair V, Kumar H. Clinicopathological features and outcome of thyroglobulin elevation and negative iodine scintigraphy (TENIS) patients with negative neck ultrasound: experience from a thyroid carcinoma clinic in India. World J Nucl Med 2021; 20 (04) 361-368
- 3 Ringel MD, Sosa JA, Baloch Z. et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid 2025; 35 (08) 841-985
- 4 Yang J, Ma Y, Gong Y, Gong R, Li Z, Zhu J. Multiple simultaneous rare distant metastases as the initial presentation of papillary thyroid carcinoma: a case report. Front Endocrinol (Lausanne) 2019; 10: 759
- 5 Chen Y, Zheng S, Zhang J, Yao S, Miao W. 68Ga-DOTA-FAPI-04 PET/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients. Ann Nucl Med 2022; 36 (07) 610-622
- 6 Ballal S, Yadav MP, Roesch F. et al. Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi with [18F]F-FDG PET/CT in radioiodine-resistant follicular-cell derived thyroid cancers. Eur J Nucl Med Mol Imaging 2023; 51 (01) 233-244
- 7 Durante C, Haddy N, Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91 (08) 2892-2899
- 8 Soe MH, Chiang JM, Flavell RR. et al. Non-iodine-avid disease is highly prevalent in distant metastatic differentiated thyroid cancer with papillary histology. J Clin Endocrinol Metab 2022; 107 (08) e3206-e3216
- 9 Toraih EA, Hussein MH, Zerfaoui M. et al. Site-specific metastasis and survival in papillary thyroid cancer: the importance of brain and multi-organ disease. Cancers (Basel) 2021; 13 (07) 1625
- 10 Shen H, Zhu R, Liu Y. et al. Radioiodine-refractory differentiated thyroid cancer: molecular mechanisms and therapeutic strategies for radioiodine resistance. Drug Resist Updat 2024; 72: 101013
- 11 Nahed BV, Alvarez-Breckenridge C, Brastianos PK. et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on the role of surgery in the management of adults with metastatic brain tumors. Neurosurgery 2019; 84 (03) E152-E155
- 12 Bussani R, De-Giorgio F, Abbate A, Silvestri F. Cardiac metastases. J Clin Pathol 2007; 60 (01) 27-34
- 13 Bussani R, Silvestri F. Neoplastic thrombotic endocarditis of the tricuspid valve in a patient with carcinoma of the thyroid. Report of a case. Pathol Res Pract 1999; 195 (02) 121-124
- 14 Hao C, Sun JP. Pericardial metastasis mass from thyroid carcinoma. In: Jing PingSun, Xing ShengYang. Comparative Cardiac Imaging. 1st ed.. John Wiley & Sons Ltd; 2018: 249-252
- 15 Baberwal P, Asopa R, Basu S. A rare and intriguing case of papillary thyroid carcinoma with tumor thrombus extending into the right ventricle: documentation with 131 I-NaI-SPECT/CT, MRI, and 18 F-FDG-PET/CT. World J Nucl Med 2024; 23 (04) 295-298
- 16 Albliwi M, Vignarajah A, Vigneswaramoorthy N. et al. Diagnostic and therapeutic challenges of cardiac metastasis in advanced malignancies: a case series and literature review. Case Rep Oncol Med 2025; 2025: 7374561
- 17 Cazacu SM, SĂndulescu LD, Mitroi G, Neagoe DC, Streba C, Albulescu DM. Metastases to the kidney: a case report and review of the literature. Curr Health Sci J 2020; 46 (01) 80-89
- 18 Kand P, Basu S. Clinicoradiological characteristics of patients with differentiated thyroid carcinoma and renal metastasis: case series with follow up. J Laryngol Rhinol Otol 2014; 128 (02) 203-208
- 19 Nair LM, Anila KR, Sreekumar A, Pradeep VM. Renal metastasis from papillary carcinoma thyroid detected by whole body iodine scan: a case report and review of the literature. Indian J Nucl Med 2016; 31 (03) 232-234
- 20 Dahl PR, Brodland DG, Goellner JR, Hay ID. Thyroid carcinoma metastatic to the skin: a cutaneous manifestation of a widely disseminated malignancy. J Am Acad Dermatol 1997; 36 (04) 531-537
- 21 Sciscent BY, Eberly HW, Goyal N, Goldenberg D. Thyroid cancer with cutaneous metastases. Ear Nose Throat J 2024; ;•••: 1455613241239533 ( e-pub ahead of print)
- 22 Herbowski L. Skeletal muscle metastases from papillary and follicular thyroid carcinomas: an extensive review of the literature. Oncol Lett 2018; 15 (05) 7083-7089
- 23 Bilgic S, Koroglu I, Sager MS, Sonmezoglu K. Iodine-negative rare gluteal muscle metastasis of papillary thyroid cancer: detected by 68Ga-DOTATATE PET/MRI and 18F-FDG PET/CT. World J Nucl Med Published online June 3, 2025
- 24 Haddad RI, Bischoff L, Ball D. et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20 (08) 925-951
- 25 Wang H, Dai H, Li Q, Shen G, Shi L, Tian R. Investigating 18F-FDG PET/CT parameters as prognostic markers for differentiated thyroid cancer: a systematic review. Front Oncol 2021; 11: 648658
- 26 Guglielmo P, Alongi P, Baratto L. et al. FAPi-based agents in thyroid cancer: a new step towards diagnosis and therapy? A systematic review of the literature. Cancers (Basel) 2024; 16 (04) 839
- 27 Rizzo A, Albano D, Dondi F. et al. Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review. Front Med (Lausanne) 2024; 11: 1381863
- 28 Ding H, Li D, Chen Y, He W, Cai L. Cutaneous metastasis of ovarian cancer on 68 Ga-FAPI PET/CT. Clin Nucl Med 2024; 49 (04) 351-352
- 29 Schlumberger M, Tahara M, Wirth LJ. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372 (07) 621-630
- 30 Reddy MM, Verma P, Basu S. Excellent objective response to lenvatinib in a patient of recurrent radioiodine refractory poorly differentiated thyroid carcinoma. World J Nucl Med 2025; •••

